Home › Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
 

Keywords :   


Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

2015-09-16 16:16:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: on type similar controlled

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
28.06Tropical Depression Two Forecast Discussion Number 1
28.06Tropical Depression Two Wind Speed Probabilities Number 1
More »